Wall Street Zen upgraded shares of Aerovate Therapeutics (NASDAQ:JBIO – Free Report) to a hold rating in a research report sent to investors on Saturday.
Aerovate Therapeutics Stock Performance
Shares of NASDAQ JBIO opened at $6.76 on Friday. Aerovate Therapeutics has a twelve month low of $6.57 and a twelve month high of $884.97. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0.11 and a beta of 0.93.
Aerovate Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than Aerovate Therapeutics
- The Basics of Support and Resistance
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What Are Earnings Reports?
- Alphabet Enters a Bull Market: Is It Time to Buy?
- How to Evaluate a Stock Before Buying
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.